Cargando…

YKL-40 as a Potential Biomarker for the Differential Diagnosis of Alzheimer’s Disease

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, associated with extensive neuronal loss, dendritic and synaptic changes resulting in significant cognitive impairment. An increased number of studies have given rise to the neuroinflammatory hypothesis in AD. It is widely accepted...

Descripción completa

Detalles Bibliográficos
Autores principales: Mavroudis, Ioannis, Chowdhury, Rumana, Petridis, Foivos, Karantali, Eleni, Chatzikonstantinou, Symela, Balmus, Ioana Miruna, Luca, Iuliana Simona, Ciobica, Alin, Kazis, Dimitrios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777884/
https://www.ncbi.nlm.nih.gov/pubmed/35056368
http://dx.doi.org/10.3390/medicina58010060
_version_ 1784637179722465280
author Mavroudis, Ioannis
Chowdhury, Rumana
Petridis, Foivos
Karantali, Eleni
Chatzikonstantinou, Symela
Balmus, Ioana Miruna
Luca, Iuliana Simona
Ciobica, Alin
Kazis, Dimitrios
author_facet Mavroudis, Ioannis
Chowdhury, Rumana
Petridis, Foivos
Karantali, Eleni
Chatzikonstantinou, Symela
Balmus, Ioana Miruna
Luca, Iuliana Simona
Ciobica, Alin
Kazis, Dimitrios
author_sort Mavroudis, Ioannis
collection PubMed
description Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, associated with extensive neuronal loss, dendritic and synaptic changes resulting in significant cognitive impairment. An increased number of studies have given rise to the neuroinflammatory hypothesis in AD. It is widely accepted that AD brains show chronic inflammation, probably triggered by the presence of insoluble amyloid beta deposits and neurofibrillary tangles (NFT) and is also related to the activation of neuronal death cascade. In the present study we aimed to investigate the role of YKL-40 levels in the cerebrospinal fluid (CSF) in the diagnosis of AD, and to discuss whether there are further potential roles of this protein in the management and treatment of AD. We conducted an online search on PubMed, Web of Science, and the Cochrane library databases from 1990 to 2021. The quantitative analysis showed that the levels of YKL-40 were significantly higher in Alzheimer’s disease compared to controls, to mild cognitive impairment (MCI) AD (MCI-AD) and to stable MCI. They were also increased in MCI-AD compared to stable MCI. The present study shows that the CSF levels of YKL-40 could be potentially used as a biomarker for the prognosis of mild cognitive impairment and the likelihood of progression to AD, as well as for the differential diagnosis between AD and MCI.
format Online
Article
Text
id pubmed-8777884
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87778842022-01-22 YKL-40 as a Potential Biomarker for the Differential Diagnosis of Alzheimer’s Disease Mavroudis, Ioannis Chowdhury, Rumana Petridis, Foivos Karantali, Eleni Chatzikonstantinou, Symela Balmus, Ioana Miruna Luca, Iuliana Simona Ciobica, Alin Kazis, Dimitrios Medicina (Kaunas) Review Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, associated with extensive neuronal loss, dendritic and synaptic changes resulting in significant cognitive impairment. An increased number of studies have given rise to the neuroinflammatory hypothesis in AD. It is widely accepted that AD brains show chronic inflammation, probably triggered by the presence of insoluble amyloid beta deposits and neurofibrillary tangles (NFT) and is also related to the activation of neuronal death cascade. In the present study we aimed to investigate the role of YKL-40 levels in the cerebrospinal fluid (CSF) in the diagnosis of AD, and to discuss whether there are further potential roles of this protein in the management and treatment of AD. We conducted an online search on PubMed, Web of Science, and the Cochrane library databases from 1990 to 2021. The quantitative analysis showed that the levels of YKL-40 were significantly higher in Alzheimer’s disease compared to controls, to mild cognitive impairment (MCI) AD (MCI-AD) and to stable MCI. They were also increased in MCI-AD compared to stable MCI. The present study shows that the CSF levels of YKL-40 could be potentially used as a biomarker for the prognosis of mild cognitive impairment and the likelihood of progression to AD, as well as for the differential diagnosis between AD and MCI. MDPI 2021-12-30 /pmc/articles/PMC8777884/ /pubmed/35056368 http://dx.doi.org/10.3390/medicina58010060 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Mavroudis, Ioannis
Chowdhury, Rumana
Petridis, Foivos
Karantali, Eleni
Chatzikonstantinou, Symela
Balmus, Ioana Miruna
Luca, Iuliana Simona
Ciobica, Alin
Kazis, Dimitrios
YKL-40 as a Potential Biomarker for the Differential Diagnosis of Alzheimer’s Disease
title YKL-40 as a Potential Biomarker for the Differential Diagnosis of Alzheimer’s Disease
title_full YKL-40 as a Potential Biomarker for the Differential Diagnosis of Alzheimer’s Disease
title_fullStr YKL-40 as a Potential Biomarker for the Differential Diagnosis of Alzheimer’s Disease
title_full_unstemmed YKL-40 as a Potential Biomarker for the Differential Diagnosis of Alzheimer’s Disease
title_short YKL-40 as a Potential Biomarker for the Differential Diagnosis of Alzheimer’s Disease
title_sort ykl-40 as a potential biomarker for the differential diagnosis of alzheimer’s disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777884/
https://www.ncbi.nlm.nih.gov/pubmed/35056368
http://dx.doi.org/10.3390/medicina58010060
work_keys_str_mv AT mavroudisioannis ykl40asapotentialbiomarkerforthedifferentialdiagnosisofalzheimersdisease
AT chowdhuryrumana ykl40asapotentialbiomarkerforthedifferentialdiagnosisofalzheimersdisease
AT petridisfoivos ykl40asapotentialbiomarkerforthedifferentialdiagnosisofalzheimersdisease
AT karantalieleni ykl40asapotentialbiomarkerforthedifferentialdiagnosisofalzheimersdisease
AT chatzikonstantinousymela ykl40asapotentialbiomarkerforthedifferentialdiagnosisofalzheimersdisease
AT balmusioanamiruna ykl40asapotentialbiomarkerforthedifferentialdiagnosisofalzheimersdisease
AT lucaiulianasimona ykl40asapotentialbiomarkerforthedifferentialdiagnosisofalzheimersdisease
AT ciobicaalin ykl40asapotentialbiomarkerforthedifferentialdiagnosisofalzheimersdisease
AT kazisdimitrios ykl40asapotentialbiomarkerforthedifferentialdiagnosisofalzheimersdisease